The EPS beat and upcoming SL-325 data readout in Q2 2026 could drive near-term volatility. Monitor for data release; positive results could trigger a significant rally given the stock's high beta. Cash runway into 2029 reduces financing risk.
Price Chart
Executive Summary
Shattuck Labs reported Q1 2026 EPS of -$0.12, beating consensus of -$0.13 by 9.1%, with zero revenue as expected. The company completed enrollment in the Phase 1 trial of SL-325 and plans to release data in Q2 2026, with a Phase 2 Crohn's disease trial expected in H2 2026. Cash runway extended into 2029 supports operations through key catalysts.
Key Financial Metrics
Key Facts
- EPS -$0.12 vs consensus -$0.13 (9.1% beat)
- Revenue $0 (in line with expectations)
- Phase 1 SL-325 trial enrollment complete; data expected Q2 2026
- Phase 2 Crohn's trial expected to start H2 2026
- Cash and equivalents $90.4M, runway into 2029
- Net loss -$14.8M vs -$13.7M YoY; per-share loss improved to -$0.13 from -$0.27 due to increased share count
Financial Impact
EPS beat of $0.01 vs consensus; no revenue impact
Risk Factors
- Phase 1 data may disappoint, leading to sharp selloff
- No approved products or revenue; reliance on successful clinical development
- High share dilution risk from warrant exercises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289733 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | 8-K | $7.18 $7.45 | ▲ +3.76% | ▲ +4.16% | $5.54 (−22.84%) |
Aug 11, 2026 10w ago | Press Release | $7.18 $7.45 | ▲ +3.76% | ▲ +4.16% | $5.54 (−22.84%) |
Jul 7, 2026 15w ago | Insider Cluster | $6.88 $6.29 | ▼ −8.58% | ▼ −9.44% | $5.54 (−19.48%) |
Jul 2, 2026 16w ago | Insider Cluster | $7.05 $7.03 | ▼ −0.28% | ▼ −1.21% | $5.54 (−21.42%) |
Jun 11, 2026 19w ago | 8-K | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 11, 2026 19w ago | 424B5 | $4.18 $4.74 | ▼ −13.40% | ▼ −12.96% | $5.54 (−32.54%) |
Jun 10, 2026 19w ago | Press Release | $4.13 $4.33 | ▼ −4.84% | ▼ −1.41% | $5.54 (−34.14%) |
Jun 9, 2026 19w ago | 424B5 | $4.13 $4.33 | ▼ −4.84% | ▼ −1.41% | $5.54 (−34.14%) |
Jun 9, 2026 19w ago | 8-K | $4.13 $4.33 | ▲ +4.84% | ▲ +1.41% | $5.54 (+34.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers